Mirae Asset Global Investments Co., Ltd. Summit Therapeutics Inc. Transaction History
Mirae Asset Global Investments Co., Ltd.
- $20 Billion
- Q2 2024
A detailed history of Mirae Asset Global Investments Co., Ltd. transactions in Summit Therapeutics Inc. stock. As of the latest transaction made, Mirae Asset Global Investments Co., Ltd. holds 20,958 shares of SMMT stock, worth $421,255. This represents 0.0% of its overall portfolio holdings.
Number of Shares
20,958
Previous 40,476
48.22%
Holding current value
$421,255
Previous $167,000
2.4%
% of portfolio
0.0%
Previous 0.0%
Shares
6 transactions
Others Institutions Holding SMMT
# of Institutions
138Shares Held
64.4MCall Options Held
1.06MPut Options Held
1.02M-
Baker Bros. Advisors LP New York, NY23.2MShares$467 Million2.41% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.82MShares$177 Million0.0% of portfolio
-
Black Rock Inc. New York, NY7.9MShares$159 Million0.0% of portfolio
-
State Street Corp Boston, MA4.12MShares$82.9 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA2.96MShares$59.6 Million0.0% of portfolio
About Summit Therapeutics Inc.
- Ticker SMMT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 201,215,008
- Market Cap $4.04B
- Description
- Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecu...